Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Restoring blood flow following an acute myocardial infarction saves lives, but results in tissue damage due to ischaemia-reperfusion injury (I/R). Ameliorating this damage is a major research goal to improve recovery and reduce subsequent morbidity due to heart failure. Both the ischaemic and reperfusion phases represent crises of cellular energy provision in which the mitochondria play a central role. This mini-review will explore the rationale and therapeutic potential of augmenting the creatine kinase (CK) energy shuttle, which constitutes the primary short-term energy buffer and transport system in the cardiomyocyte. Proof-of-principle data from several transgenic mouse models have demonstrated robust cardioprotection by either raising myocardial creatine levels or by overexpressing specific CK isoforms. The effect on cardiac function, high-energy phosphates and myocardial injury will be discussed and possible directions for future research highlighted. We conclude that the CK system represents a viable target for therapeutic intervention in I/R injury; however, much needed translational studies will require the development of new pharmacological tools.

Original publication

DOI

10.1042/BST20170504

Type

Journal article

Journal

Biochem Soc Trans

Publication Date

19/10/2018

Volume

46

Pages

1119 - 1127

Keywords

bioenergetics, cardioprotection, creatine kinase, ischaemia–reperfusion injury, Animals, Creatine Kinase, Heart Failure, Humans, Mice, Mice, Transgenic, Mitochondria, Liver, Myocardial Infarction, Myocardial Reperfusion Injury, Myocardium, Myocytes, Cardiac, Phosphates, Reperfusion Injury, Translational Medical Research